NATIONAL COMPREHENSIVE CANCER NETWORK

Over the past few years, there have been significant developments in the treatment of multiple myeloma. However, the therapies are not cures, so all patients will eventually relapse. In a recent real-world study, researchers looked to understand the patterns and outcomes for patients who were double-exposed, double-class refractory, and triple-class refractory to therapy... *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for multiple myeloma define early relapsed as those occurring with 1-3 prior therapies... Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2023. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed May 17, 2023. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or..

Also known as: National Comprehensive Cancer Network, Inc